228 related articles for article (PubMed ID: 2555056)
21. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
23. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.
Yu HR; Schultz RM
Cancer Res; 1990 Dec; 50(23):7623-33. PubMed ID: 1701350
[TBL] [Abstract][Full Text] [Related]
24. Heparin selectively inhibits synthesis of tissue type plasminogen activator and matrix deposition of plasminogen activator inhibitor 1 by human mesangial cells.
Hagège J; Delarue F; Peraldi MN; Sraer JD; Rondeau E
Lab Invest; 1994 Dec; 71(6):828-37. PubMed ID: 7807964
[TBL] [Abstract][Full Text] [Related]
25. Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells.
Niiya M; Niiya K; Kiguchi T; Shibakura M; Asaumi N; Shinagawa K; Ishimaru F; Kiura K; Ikeda K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2003 Nov; 52(5):391-8. PubMed ID: 12908082
[TBL] [Abstract][Full Text] [Related]
26. Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.
Buø L; Bjørnland K; Karlsrud TS; Kvale D; Kjønniksen I; Fodstad O; Brandtzaeg P; Johansen HT; Aasen AO
Anticancer Res; 1994; 14(6B):2445-51. PubMed ID: 7872665
[TBL] [Abstract][Full Text] [Related]
27. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
Swiercz R; Wolfe JD; Zaher A; Jankun J
Clin Cancer Res; 1998 Apr; 4(4):869-77. PubMed ID: 9563880
[TBL] [Abstract][Full Text] [Related]
28. Effects of tiaprofenic acid on plasminogen activators and inhibitors in human OA and RA synovium.
Pelletier JP; McCollum R; Cloutier JM; Martel-Pelletier J
Br J Rheumatol; 1992; 31 Suppl 1():19-26. PubMed ID: 1555050
[TBL] [Abstract][Full Text] [Related]
29. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
Sugiura Y; Ma L; Sun B; Shimada H; Laug WE; Seeger RC; DeClerck YA
Cancer Res; 1999 Mar; 59(6):1327-36. PubMed ID: 10096567
[TBL] [Abstract][Full Text] [Related]
30. [Effect of cyclic AMP and phorbol ester on PAI-2 synthesis in a leukemic cell line PL-21 and on u-PA secretion in a pre-B cell lymphoma cell line RC-K8].
Niiya K; Sakuragawa N
Nihon Rinsho; 1992 Feb; 50(2):325-9. PubMed ID: 1319513
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
32. Mouse trophoblastic cell lines: II--Relationship between invasive potential and proteases.
Sharma RK
In Vivo; 1998; 12(2):209-17. PubMed ID: 9627804
[TBL] [Abstract][Full Text] [Related]
33. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
34. Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase.
Schwartz-Albiez R; Heidtmann HH; Wolf D; Schirrmacher V; Moldenhauer G
Br J Cancer; 1992 Jan; 65(1):51-7. PubMed ID: 1310252
[TBL] [Abstract][Full Text] [Related]
35. Differential protease expression by cutaneous squamous and basal cell carcinomas.
Sappino AP; Belin D; Huarte J; Hirschel-Scholz S; Saurat JH; Vassalli JD
J Clin Invest; 1991 Oct; 88(4):1073-9. PubMed ID: 1918364
[TBL] [Abstract][Full Text] [Related]
36. Correlation between urokinase-type plasminogen activator production and the metastatic ability of human rectal cancer cells.
Marutsuka K; Suzumiya J; Kataoka H; Komada N; Koono M; Sumiyoshi A
Invasion Metastasis; 1991; 11(4):181-91. PubMed ID: 1765431
[TBL] [Abstract][Full Text] [Related]
37. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
[TBL] [Abstract][Full Text] [Related]
38. [Plasminogen activator inhibitors from neoplastic tissues].
Mirowski M; Wierzbicki R
Postepy Hig Med Dosw; 1991; 45(1-2):119-27. PubMed ID: 1923993
[TBL] [Abstract][Full Text] [Related]
39. Complex expression of the genes coding for plasminogen activators and their inhibitors in HeLa-smooth muscle cell hybrids.
Laug WE; Cao XR; T'Ang A; Pasquale S; Mundy R; Coensgen-Luna M; Weissman B
Cell Growth Differ; 1992 Mar; 3(3):191-7. PubMed ID: 1633110
[TBL] [Abstract][Full Text] [Related]
40. Specificity of response in hamster cells induced to produce plasminogen activator by the tumor promoter, 12-O-tetradecanoylphorbol-13-acetate.
Christman JK; Copp RP; Pedrinan L; Whalen CE
Cancer Res; 1978 Nov; 38(11 Pt 1):3854-60. PubMed ID: 81105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
